Back to Journals » International Journal of Chronic Obstructive Pulmonary Disease » Volume 4

Study design considerations in a large COPD trial comparing effects of tiotropium with salmeterol on exacerbations

Authors Kai-Michael Beeh, Bettina Hederer, Thomas Glaab, Achim Müller, Maureen Rutten-van Moelken, et al

Published 26 February 2009 Volume 2009:4 Pages 119—125

DOI https://doi.org/10.2147/COPD.S4676

Review by Single-blind

Peer reviewer comments 2

Kai-Michael Beeh1, Bettina Hederer2, Thomas Glaab2, Achim Müller2, Maureen Rutten-van Moelken3, et al

1insaf–Respiratory Research Institute, Wiesbaden, Germany; 2Boehringer Ingelheim, Ingelheim, Germany; 3Institute for Medical Technology Assessment, Erasmus Medical Centre, Rotterdam, The Netherlands, et al

Abstract: Currently available long-acting inhaled bronchodilators (tiotropium, salmeterol, formoterol) have demonstrated beneficial effects on exacerbations in placebo-controlled trials. However, there have been no direct comparisons of these drugs with exacerbations as the primary outcome and consequently COPD treatment guidelines do not indicate a preference for either bronchodilator. Therefore, an international, randomized, double-blind, double-dummy, parallelgroup clinical trial has been designed to investigate the comparative efficacy of 2 long-acting bronchodilators tiotropium 18 μg daily and salmeterol 50 μg bid on exacerbations. The trial will include at least 6800 randomized patients with diagnosis of COPD, 10 pack-year history of smoking, post-bronchodilator FEV1 ≤ 70% predicted, and a history of exacerbations in the previous year. The primary endpoint is time to first COPD exacerbation. Secondary endpoints include number of exacerbations and time to premature discontinuation of trial medication. The trial has been designed to address several of the challenges in studying exacerbations in a controlled trial by a symptom and event-based definition of exacerbations, frequent follow-up contacts, selection of time to first event as the primary endpoint and using exposure adjusted analysis when examining number of events. Other challenges in designing exacerbation trials such as differential discontinuation and follow-up of discontinued patients are discussed.

Keywords: chronic obstructive pulmonary disease, exacerbation, salmeterol, study methodology, tiotropium

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF] 

 

Readers of this article also read:

Synthesis and characterization of multifunctional hybrid-polymeric nanoparticles for drug delivery and multimodal imaging of cancer

Tng DJH, Song P, Lin G, Soehartono AM, Yang G, Yang C, Yin F, Tan CH, Yong KT

International Journal of Nanomedicine 2015, 10:5771-5786

Published Date: 15 September 2015

Visual fields in a chloroquine treatment

García-Domene MC, Díez-Ajenjo MA, de Fez MD, Luque MJ

Clinical Optometry 2014, 6:59-70

Published Date: 30 September 2014

The therapeutic effect of monocyte chemoattractant protein-1 delivered by an electrospun scaffold for hyperglycemia and nephrotic disorders

Yong C, Wang ZX, Zhang X, Shi XM, Ni ZJ, Fu H, Ding GS, Fu ZR, Yin H

International Journal of Nanomedicine 2014, 9:985-993

Published Date: 17 February 2014

Paclitaxel-Fe3O4 nanoparticles inhibit growth of CD138–  CD34– tumor stem-like cells in multiple myeloma-bearing mice

Yang C, Wang J, Chen D, Chen J, Xiong F, Zhang H, Zhang Y, Gu N, Dou J

International Journal of Nanomedicine 2013, 8:1439-1449

Published Date: 12 April 2013

ABCB1 haplotype and OPRM1 118A > G genotype interaction in methadone maintenance treatment pharmacogenetics

Barratt DT, Coller JK, Hallinan R, Byrne A, White JM, Foster DJR, Somogyi AA

Pharmacogenomics and Personalized Medicine 2012, 5:53-62

Published Date: 18 April 2012

Update on pediatric dystonias: etiology, epidemiology, and management

Fernández-Alvarez E, Nardocci N

Degenerative Neurological and Neuromuscular Disease 2012, 2:29-41

Published Date: 12 April 2012